Form 4: VolitionRx Director Innes Acquires Shares Through RSU Vesting, Cancels Unvested Units

Director Guy Archibald Innes acquired 5,000 shares of VolitionRx Ltd common stock through the vesting of restricted stock units, while also having 6,500 unvested RSUs cancelled.

Summary

• On August 15, 2024, Guy Archibald Innes, a director of VolitionRx Ltd, acquired 5,000 shares of common stock.
• This acquisition was a result of the vesting of restricted stock units (RSUs) awarded on September 28, 2023, under the company's 2015 Stock Incentive Plan.
• The RSUs were subject to both performance-based and time-based vesting conditions.
• Certain performance goals were met, leading to the vesting of rights for 5,000 RSUs.
• These RSUs are also subject to a 3-year time-based vesting schedule.
• Additionally, 6,500 RSUs that did not meet the performance goals were cancelled on August 15, 2024.
• Innes also has indirect ownership of 1,400,000 shares through The Innes Family Bare Trust 2023, 356,000 shares through The Dill Faulkes Educational Trust Limited, and other shares through family members.
• Following the reported transaction, Innes directly owns 256,683 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of RSUs suggests some performance goals were met, but the cancellation of other RSUs indicates some goals were not achieved. Overall, it's a routine insider transaction.

Positives

• The vesting of RSUs indicates that certain corporate performance goals were achieved, which could be seen as a positive sign for the company.

Negatives

• The cancellation of 6,500 RSUs suggests that some performance goals were not met, which could be a concern.

Risks

• The value of the acquired shares is subject to market fluctuations, which could impact the director's investment.
• Future vesting of RSUs is dependent on continued performance and time-based vesting requirements.

Future Outlook

The reporting person will receive additional shares of common stock upon the vesting of the remaining RSUs according to the time-based vesting schedule.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's confidence in the company's prospects.

Comparison to Industry Standards

• Insider ownership is a common metric used to assess alignment between management and shareholder interests.
• Comparing Innes's total ownership (direct and indirect) to that of directors in similar biotechnology companies could provide insights into his level of investment relative to peers.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) are in a similar space, and their insider ownership structures could be used as a benchmark.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects insider activity and changes in ownership structure.
• Employees may be affected by the performance goals tied to the RSU vesting, as their achievement impacts executive compensation.

Next Steps

• The reporting person will continue to receive shares as the remaining RSUs vest according to the time-based schedule.

Key Dates